1. 1 MILO/ENGOT-OV11: Phase-3 study of binimetinib versus physician's choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. (18th September 2019) Authors: Grisham, R; Monk J, B; Banerjee, S; Coleman L, R; Oza M, A; Oehler K, M; Kalbacher, E; Mirza Raza, M; del Campo M, J; Marth, C; Westermann, A; Pignata, S; Colombo, N; Cibula, D; Hilpert, F; Aghajanian, C; Drill, E; Sandor, V; Boyd P, A; Vergote, I Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 3 Page Start: A1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Dilution of molecular-pathologic gene signatures (MPG) by parameter unrelated to tumor biology (UTB) may prevent prediction of the resection status after debulking surgery in patients with advanced ovarian cancer. (1st November 2019) Authors: Heitz, F; Kommoss, S; Tourani, R; Grandelis, A; Uppendahl, L; Aliferis, C; Burges, A; Wang, C; Canzler, U; Wang, J; Belau, A; Prader, S; Hanker, L; Ma, S; Ataseven, B; Hilpert, F; Schneider, S; Sehouli, J; Kimmig, R; Kurzeder, C Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. EP1168 The influence of obesity on tumor recurrence in vulvar cancer patients. (1st November 2019) Authors: Klapdor, R; Hillemanns, P; Wölber, L; Jückstock, J; Hilpert, F; de Gregorio, N; Hasenburg, A; Sehouli, J; Fürst, ST; Strauß, HG; Baumann, K; Thiel, F; Mustea, A; Meier, W; Harter, P; Wimberger, P; Hanker, L; Schmalfeldt, B; Mahner, S Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A605 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. EP869 Treatment of ovarian cancer in Germany from 2004–2016: results of a nationwide quality assurance program (QS Ovar). (1st November 2019) Authors: Harter, P; Pfisterer, J; Hilpert, F; Sehouli, J; Lamparter, C; Kerkmann, M; du Bois, A Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A471 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P142 Results of the 3rd interim analysis of C-Patrol: a non-interventional study on olaparib in german routine clinical practice. (1st November 2019) Authors: Marmé, F; Hilpert, F; Welslau, M; Grabowski, JP; Seitz, J; El-Balat, A; Hartkopf, AD; Glowik, R; Sehouli, J Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy. (18th December 2017) Authors: Friedlander, M; Rau, J; Lee, C K; Meier, W; Lesoin, A; Kim, J -W; Poveda, A; Buck, M; Scambia, G; Shimada, M; Hilpert, F; King, M T; Debruyne, P; Bologna, A; Malander, S; Monk, B J; Petru, E; Calvert, P; Herzog, T J; Barrett, C Journal: Annals of oncology Issue: Volume 29:Number 3(2018) Page Start: 737 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗